Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals (ACAD) and maintained a $42 price target.
February 02, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals with a $42 price target.
The reiteration of an Overweight rating and a maintained price target of $42 by a reputable analyst suggests a positive outlook for ACADIA Pharmaceuticals. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100